Off-Label Risks: Compliance Matters Now More Than Ever
from DarshanTalks Podcast Hosted by Darshan Kulkarni
Send us Fan Mail We shed light on the complexities surrounding off-label promotion and reimbursement in the pharmaceutical industry. We discuss the following: What does off-label mean from a reimbursement standpoint? Lessons from the US v. Eli Lilly 2009 case How do recent court decisions impact off-label promotion? United States v. Caronia and US v. Facteau How are weight loss drugs, initially approved for treating diabetes, reimbursed within Medicare and Medicaid? How are compounded drugs reimbursed? Could a company be held accountable for off-label use of a drug due to compounded products? Are weight loss drugs exempted from reimbursement? Support the show www.kulkarnilawfirm.com
Embed this episode
No transcript yet.